BridgeBio Oncology Therapeutics (BBOT) Other Accumulated Expenses (2024 - 2026)

BridgeBio Oncology Therapeutics (BBOT) posted Other Accumulated Expenses of $545000.0 for Q1 2026, up 127.08% sequentially from $240000.0 in Q4 2025.

BridgeBio Oncology Therapeutics (BBOT) Other Accumulated Expenses (2024 - 2026) Analysis & Trends

BridgeBio Oncology Therapeutics has reported Other Accumulated Expenses for 3 years, with the latest figure at $545000.0 in Q1 2026.

Quarterly Other Accumulated Expenses changed N/A year-over-year to $545000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $545000.0 (changed N/A YoY) and the FY2025 annual result came in at $240000.0, up 44.58% from the prior year.
Other Accumulated Expenses climbed to $545000.0 in Q1 2026 per BBOT's latest filing, from $240000.0 in the prior quarter.
Over five years, Other Accumulated Expenses peaked at $545000.0 in Q1 2026 and troughed at $166000.0 in Q4 2024.
A 3-year average of $282250.0 and a median of $209000.0 in 2025 frame the typical range for Other Accumulated Expenses.
The widest YoY moves for Other Accumulated Expenses: up 44.58% in 2025, down 44.58% in 2025.
Over 3 years, Other Accumulated Expenses stood at $166000.0 in 2024, then jumped by 44.58% to $240000.0 in 2025, then surged by 127.08% to $545000.0 in 2026.
According to Business Quant data, Other Accumulated Expenses over the past three periods registered $545000.0, $240000.0, and $178000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	BridgeBio Oncology Therapeutics	726.38 Mn	500.67 Mn	-

Download Data